COVID-19 Active Research Experience (CARE)

IQVIA Pty Ltd35,278 enrolled

Overview

COVID-19 Active Research Experience (CARE) is an observational, direct-to-participant, web-based, longitudinal study of adults with COVID-19 or COVID-19 like illness or who were vaccinated against COVID-19 to better understand risk factors, symptoms, and treatments for COVID-19 illness and vaccine safety and effectiveness.

This is an observational, direct-to-participant, web-based, longitudinal study of adults with COVID-19 or COVID-19 like illness to better understand risk factors, symptoms, and treatments for COVID-19 illness and vaccine safety and effectiveness. Upon consent and enrollment, participants will complete an initial baseline survey reporting their demographics, relevant medical history, testing, vaccination, symptoms, use of prescription medications as well as use of supplements and other factors. The study follow-up period is 12 months. During the first month of follow-up participants will be invited to complete a symptom diary weekly to gauge symptom progression and severity and to provide updates on pharmaceutical and non-pharmaceutical interventions as well as healthcare encounters. Reporting will then reduce to monthly for Month 2 through 12.

Study Type

OBSERVATIONAL

Enrollment

35,278

Conditions

COVID-19

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult (18 years or older) * Currently living in the US or UK * Have regular access to a computer, smartphone or tablet and sufficient internet to support registry demands (note: this registry is designed to operate well even in regions with low bandwidth) * Willing and able to provide informed consent * Willing and able to follow the procedures of the study Participants must also meet at least one of the following conditions: * Have COVID-19 or COVID-19 like symptoms * Received a COVID-19 vaccine * Potential exposure to COVID-19 Exclusion Criteria: * Unable to provide informed consent * Unable to perform the requested study tasks and unable or unwilling to assign a proxy informant to complete the tasks

Locations (2)

IQVIA

Cambridge, Massachusetts, United States

IQVIA

London, United Kingdom

Outcomes

Primary Outcomes

COVID-19 symptom occurrence and severity

Occurrence and severity of potential COVID-19 symptoms as reported by participants in the survey

Time frame: 12 months

COVID-19 treatments

Prescription treatments for COVID-19 as reported by participants in the survey

Time frame: 12 months

COVID-19 risk factors

Assess potential role of comorbidities and concomitant medications on COVID-19 occurrence and severity

Time frame: 12 months

Occurrence and severity of COVID-19 infection after vaccination

Occurrence and severity of COVID-19 infection as reported by participants after SARS-CoV-2 vaccine

Time frame: 12 months

Occurrence of medically attended events after vaccination

Occurrence of medically attended events as reported by participants after after SARS-CoV-2 vaccine

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.